Skip to main content

Table 4 Outcomes with dabigatran compared with warfarin

From: Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

End points Dabigatran 110 mg ×2 Dabigatran 150 mg ×2 Warfarin NNT/NNH: dabigatran 110 mg NNT/NNH: dabigatran 150 mg
Primary outcomes (%) 1.53 1.11 1.69 625 172
Myocardial infarction (%) 0.7 0.7 0.5 500 500
Mortality (%) 3.8 3.6 4.1 330 200
Major bleeding (%) 2.7 3.1 3.4 143 333
Intracranial bleeding (%) 0.2 0.3 0.7 200 250
Net clinical benefits (%) 7.1 6.9 7.6 200 143
  1. NNH, number needed to harm; NNT, number needed to treat. Net clinical benefits: vascular events, death and major bleeding. Data from the RE-LY trial [16].